en · de · es · fr · pt
cjc-1295-notes.peptides6608.com › Data › Receptor Action And Clearance — Deep Dive

Receptor Action And Clearance — Deep Dive

By Editorial Desk · published 2025-09-26 · last reviewed 2025-10-15 · Data

drug affinity complex raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

Reviewed 2025-10-15. Anything still debated is marked as such rather than presented as settled.

Receptor Action and Clearance

Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.

Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.

Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.

CJC-1295 Background and Mechanism

Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.

CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.

Cjc-1295 at a glance

PropertyValueNotes
Primary targetGHRH receptorPresent on pituitary somatotroph cells
Signal pathwayGs, cyclic AMP, protein kinase ASequence follows receptor activation
Main measured effectGrowth hormone releaseInsulin-like growth factor 1 shifts indirectly
Half-life, binding formSeveral daysExtended through serum albumin association
Half-life, unmodified formAbout 30 minutesLimited mainly by enzymatic cleavage

Molecular Background and Naming

Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.

The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.

CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.

Related pages on this site

Identity and Naming History

CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.

The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.

Reference notes

== Precautions == THF is a relatively acutely nontoxic solvent, with the median lethal dose (LD50) comparable to that for acetone. However, chronic exposure is suspected of causing cancer. Reflecting its remarkable solvent properties, it penetrates the skin, causing rapid dehydration. It is highly flammable. THF dissolves or penetrates most polymer glove materials in a very short period of time; only Linear low-density polyethylene (LLDPE) laminated gloves are capable of protecting against it for long time periods, similar to most ketones. Polyvinyl alcohol (PVA) coated gloves are capable of providing protection for nearly an hour, but because PVA is water soluble they are only effective in low humidity environments and when working with anhydrous solvents. Even very thick nitrile or nitrile-neoprene gloves degrade in under 10 minutes. One danger posed by THF is its tendency to form explosive peroxides upon reaction with air:

=== Signalling === Once cleaved, PAR1 can activate G-proteins that bind to several locations on its intracellular loops. For example, PAR1 in conjunction with PAR4 can couple to and activate G-protein G12/13 which in turn activates Rho and Rho kinase. This pathway leads to the quick alteration of platelet shape due to actin contractions that lead to platelet mobility, as well as the release of granules which are both necessary for platelet aggregation. Coupling can also occur with Gq, leading to phospholipase C-β activation; this pathway results in the stimulation of protein kinase C (PKC) which impacts platelet activation. Additionally, both PAR1 and PAR4 can couple to G-protein q which stimulates intracellular movement for Calcium ions that serve as second messengers for platelet activation. This also activates protein kinase C which stimulates platelet aggregation and therefore blood coagulation further down the pathway.

Our main concern is the liberation of the blacks." Elsewhere, Biko argued that it was the responsibility of a vanguard movement to ensure that, in a post-apartheid society, the black majority would not seek vengeance upon the white minority. He stated that this would require an education of the black population in order to teach them how to live in a non-racial society.

== Epidemiology == An estimate of in the order of 1000 dive injuries per year occur in the United States and Canada. Many of these involve barotrauma, with nearly 50% of reported injuries involving middle ear barotrauma. Diving injuries tend to correlate with trait anxiety and a tendency to panic, lack of experience, advancing age and reduction in fitness, alcohol usage, obesity, asthma, chronic sinusitis and otitis.

=== Biological characteristics === Like other aptamers, L-RNA aptamers are able to bind molecules such as peptides, proteins, and substances of low molecular weight. The affinity of L-RNA aptamers to their target molecules often lies in the pico to nanomolar range and is thus comparable to antibodies. L-RNA aptamers themselves have low antigenicity. In contrast to other aptamers, L-RNA aptamers have high stability in blood serum, since they are less susceptible to be cleaved hydrolytically by enzymes. They are excreted by the kidneys in a short time due to their low molar mass (which is below the renal threshold). L-RNA aptamers modified with a higher molar mass, such as PEGylated L-RNA aptamers, show a prolonged plasma half-life.

Sources: en.wikipedia.org

Reference notes

This PFS benefit was consistent across subgroups with individual high-risk cytogenetic abnormalities, including patients with del(17p). PFS was also longer with IRd versus placebo- in patients with 1q21 amplification, and in the "expanded high-risk" group, defined as those with high-risk cytogenetic abnormalities and/or 1q21 amplification. IRd demonstrated substantial benefit compared with placebo in relapsed/refractory multiple myeloma patients with high-risk and standard-risk cytogenetics, and improves the poor PFS associated with high-risk cytogenetic abnormalities.

Combination of TMA-2 with harmaline or ibogaine has been reported to result in long-lasting episodes complicated by severe psychomotor agitation. TMA-2's affinity (Ki) for the serotonin 5-HT2A receptor has been found to be 1,300 nM. Its EC50Tooltip half-maximal effective concentration at the receptor was 190 nM and its EmaxTooltip maximal efficacy was 84%. The drug was also active at the serotonin 5-HT2B receptor and, to a much lesser extent, at the serotonin 5-HT2C receptor. In an earlier study, its affinities (Ki) were 1,650 nM at the serotonin 5-HT2 receptor and 46,400 nM at the serotonin 5-HT1 receptor. TMA-2 is inactive at the monoamine transporters. It was inactive at the mouse trace amine-associated receptor 1 (TAAR1), whereas it bound to the rat TAAR1 with an affinity (Ki) of 3,100 nM and was not assessed at the human TAAR1. In terms of metabolism, TMA-2 is known to be at least partially O-demethylated in animals in vivo. It might produce 2,4,5-trihydroxyamphetamine (THA) as a metabolite. The pharmacokinetics and metabolism of TMA-2 in humans are unknown.

Selenium has six natural isotopes that occur in significant quantities, along with the trace isotope 79Se, which occurs in minute quantities in uranium ores. Five of these isotopes are stable: 74Se, 76Se, 77Se, 78Se, and 80Se. The last three also occur as fission products, along with 79Se, which has a half-life about 330,000 years, and 82Se, which has the very long half-life of 8.76×1019 years as it decays via double beta decay to krypton-82 and for practical purposes can be considered to be stable. There are 23 other unstable isotopes that have been characterized, the longest-lived after 79Se being 75Se with its half-life 119.78 days, 72Se at 8.40 days, and 73Se at 7.15 hours. The others are all under an hour and most do not exceed 38 seconds.

On 7 April, The Rafi'-Nia synagogue in central Tehran was destroyed in an airstrike. Israel said that the building was destroyed due to collateral damage and that it was never meant to be the direct target of the airstrike. The same day, US forces began strikes on Kharg Island. In response, Iran said its restraint in targeting oil infrastructure in the region would no longer apply. Trump posted to Truth Social that "a whole civilization will die tonight, never to be brought back again", causing international concern that Trump would use nuclear weapons. The Secretary General of Amnesty International said that Trump's statement "may constitute a threat to commit genocide". Multiple right-wing commentators and many Democrats condemned the post, and some called for him to be removed through the 25th Amendment. The White House denied considering using nuclear weapons and later said that "only the president knows" what he would do on Iran. A leaked US intelligence report concluded that Iran retained 70% of missiles and launchers at this point, despite Trump claims regarding "destruction" of Iran's military. In the United Nations Security Council, China and Russia vetoed a Bahraini-led draft resolution calling on member states to coordinate efforts to protect commercial shipping in the Strait of Hormuz, with Chinese representative Fu Cong stating that adopting such a draft when the U.S. was threatening the survival of a civilization would send the wrong message.

Sources: en.wikipedia.org

Frequently asked questions

Which receptor does the compound target?

It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.

How does the albumin-binding group alter behavior?

It links the peptide to serum albumin after administration, which delays removal from circulation. Reported half-life shifts from roughly half an hour to several days as a result.

What do studies generally measure?

Most published work tracks serum growth hormone and insulin-like growth factor 1 over time. Sampling schedules and assay methods vary enough that figures are not directly comparable across reports.

What distinguishes CJC-1295 from natural GHRH?

The synthetic peptide keeps the receptor-binding region of GHRH but carries substitutions that resist enzymatic cleavage. In the DAC version, an added group also anchors the molecule to albumin, extending its presence in the bloodstream.

Network